Efficacy of nimotuzumab (hR3) conjugated with 131I or 90Y in laryngeal carcinoma xenograft mouse model
- 2 March 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of Radiation Biology
- Vol. 97 (5), 704-713
- https://doi.org/10.1080/09553002.2021.1889703
Abstract
The humanized monoclonal antibody hR3, both alone and in combination with other chemotherapeutic agents and radiotherapy, can be used to treat head and neck cancers. Substantial progress has been made in the development of targeted radioimmunotherapy using iodine-131 (131I) and yttrium-90 (90Y) radioisotopes in recent years. In the present study, we examined the efficacy of hR3 conjugated with 131I or 90Y to inhibit tumor growth in a laryngeal carcinoma xenograft tumor model. hR3 was labeled with 131I or 90Y to generate the conjugates 131I-hR3 or 90Y-hR3. The conjugates were incubated with HEp-2 laryngeal carcinoma cells to evaluate binding capacity. The efficacy of the labeled hR3 conjugates to treat laryngeal cancer was also evaluated in nude mice inoculated with HEp-2 tumors. The purified radioimmunoconjugates with specific activities of 187–191 MBq/mg had radiochemical purity >98% and >80% immunoreactivity with HEp-2 cells. Mice with HEp-2 xenografts treated with 131I-hR3 or 90Y-hR3 showed reduced tumor volume and improved survival rates compared to the untreated control group and the group treated with unlabeled hR3. At equivalent doses, radioimmunotherapeutic hR3 labeled with 90Y had increased tumor inhibition activity compared to hR3 labeled with 131I. 131I-hR3 and 90Y-hR3 are promising targeted radiopharmaceuticals for treatment of head and neck cancers, especially laryngeal cancers.Keywords
Funding Information
- Ministry of Science and Technology (KC05.14/11-15)
- Vietnam National Foundation for Science and Technology Development (106-YS.06-, .22)
- IAEA Coordinated Research (4)
This publication has 23 references indexed in Scilit:
- 177Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma ModelMolecular Pharmaceutics, 2014
- Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagusInternational Journal of Clinical Oncology, 2013
- Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptorJournal of Labelled Compounds and Radiopharmaceuticals, 2013
- Preclinical Evaluation of 177Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor–Overexpressing TumorsCancer Biotherapy & Radiopharmaceuticals, 2011
- Cancer radioimmunotherapyImmunotherapy, 2011
- Biodistribution and anti-tumor activities of the 131I-labeled rituximab in nude mice bearing human Burkitt’s lymphomaClinical Oncology and Cancer Research, 2009
- Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopesNature Protocols, 2006
- Determination of Immunoreactive Fraction of Radiolabeled Monoclonal Antibodies: What Is an Appropriate Method?Cancer Biotherapy & Radiopharmaceuticals, 2004
- Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ionsAnalytical Biochemistry, 1984
- Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excessJournal of Immunological Methods, 1984